Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis

20th July 2018 Uncategorised 0

Allergan, Molecular Partners’ abicipar has shown non-inferiority to Novartis’ Lucentis but with fewer injections in late-stage trials involving patients with neovascular age-related macular degeneration.

More: Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis
Source: News